- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
TikTok’s nearly 700 million users seek medical advice from random individuals and charlatans, since anyone can claim to be a medical expert on this raging social media machine.
Dr. Google is also working overtime, receiving more than one billion healthcare questions every day.
Web MD is recording over one billion searches a year, too.
When you combine this voracious hunger for digital diagnosis, symptom checkers and immediate medical assistance, with a global mobile app market whose revenues had already hit $365 billion in 2018, and are now on track to generate over $935 billion by 2023 ...
You get one of the best bets on disrupting the virtual medicine industry to date. You get Big Tech built by doctors for doctors in the Global Library of Medicine (GLM).
You get Cara, the new, sophisticated AI, powered by the unique Global Library of Medicine, that has been trained by hundreds of doctors to think just like them.
Cara will be launching at the end of November, marking the first time in our medical history that we can check our symptoms online, at the touch of a button, and truly trust what we are being told.
Over the past five years, Treatment.com (CSE: TRUE; OTC: TREIF) has been developing the world’s next-generation AI symptom checker, picking up where the billions of requests were left hanging by Google and WebMD … and certainly by TikTok.
Now, the app is about to launch as Treatment Mobile with an intelligent digital assistant, Cara, with over 400 diagnoses by a global team of hundreds of doctors who are adding more every day.
A Digital Fix for a Broken Healthcare System
An overwhelming majority of Americans find the healthcare system impossible to navigate.
Nearly three-quarters have no idea how they will afford their healthcare.
Those two facts have led to a shocking increase in at-home health solutions.
Need a healthcare big tech vendor who knows North American Healthcare
From 2019 to 2020—even before the COVID-19 outbreak—telemedicine grew by 46%.
In 2020 alone, wellness apps were downloaded 1.2 billion times.
Major investment into the telemedicine space combined with a massive increase in uptake and rapidly rising favor among consumers has seen telehealth increase 38X so far in 2021 from pre-COVID levels.
In April 2020, right at the start of the pandemic, telehealth use was 78X higher than in February 2020, according to McKinsey.
Total VC investment into the digital health space in H1 2021 was $14.7 billion. That’s more than VC investment for all of 2020, and twice the amount for 2019. That leads McKinsey to project that 2021 could see total investment in the sector hit $30 billion.
The bottom line is this: American healthcare is broken, and digital offerings are a major element of the fix. Cara steps in at exactly the right time to provide the first sophisticated AI that can help bring it all together. This is where big money is going in the healthcare sector.
The Digital Doctor Is In
Working with the University of Minnesota Medical School, Treatment.com (CSE: TRUE; OTC: TREIF) has gathered the best doctors and tech engineers that built the Global Library of Medicine (GLM) from around the world to teach Cara to do two things that no other digital health platform has been able to do successfully:
Think like a real doctor
Provide consumers with a personalized health assessment and full-on health management
Cara integrates everything by providing consumers with a bridge to wellness, telemedicine, pharma and health products ...
Cara asks you questions about your symptoms and then sorts through millions of pieces of information that include historical medical cases, demographic data and advances in medical knowledge. The end result is a more accurate recommendation than any other digital tool in the world.
Cara helps you understand what your symptom could be. It helps you monitor and track health changes and understand your general health and prevent illness. It gives you personalized support and follow-up and even allows you to track and manage your entire family.
And it can all be integrated with Apple Health Kit, Apple Watch and FitBit.
Treatment’s AI has been so effective, in fact, that the University of Minnesota Medical School licensed it to test medical students.
How Does Cara Make Money?
The initial app will be free, but there is an impressive scalability here.
This is how the wildly lucrative world of apps works. Once the upfront costs of development and AI learning are paid for, it’s all revenue, all the time. And app revenue streams are recurring, which is exactly why the mobile app industry continues to surge.
Consumers will pay for recommendations through premium app subscriptions, and Treatment.com’s next move with Cara will be to add a series of paid plugins for everything from dermatology specialty segments, to cardiology.
Additionally, Treatment.com will seek health and wellness partners to integrate to access qualified referrals and improve efficiencies, while simultaneously reducing costs.
There are three revenue-generating avenues here: corporate licenses, health and wellness products and university medical school training.
But the biggest value here is that Cara is a goldmine of data …
Cara’s access to individualized health trends will help insurance providers and governments to provide better health services.
In healthcare, big data like this helps avoid preventable diseases by detecting them in their early stages.
The market for big data analytics in healthcare could be worth an astounding $68 billion by 2025, and Treatment.com will have a major advantage with Cara.
WebMD—a private company—is valued at $2.8 billion, and it doesn’t even have any AI to back it up.
Treatment.com, (CSE: TRUE; OTC: TREIF) which listed on the Canadian Securities Exchange on April 19th, 2021, is about to launch a healthcare app that could completely change the way we view and access healthcare.
Global Medical and AI Expertise
Founded by John Fraser and Dr. Kevin Peterson, Treatment.com International Inc. (CSE: TRUE)(OTC:TREIF) is a sophisticated big-tech setup from the roots up.
Fraser is a computer scientist and entrepreneur with a background in healthcare technology. He’s a 20-year IT software veteran who has done this before. He sold his first unicorn—Vision Share (now Abilities Network)—for over $1 billion.
Dr. Peterson is a leading doctor and tenured professor at the University of Minnesota Medical School. He was also the architect of an international disease surveillance and research system, the first such in the world.
Add to this a global team of doctors in the United States, Canada, Singapore, India, Ethiopia and South Africa and you have the makings of the most intelligent AI symptom checker and health care management platform on the planet. Again, that’s why it’s been licensed to train medical students at the University of Minnesota.
The Next Healthcare Wave
The healthcare industry is overripe for disruption, and it’s being disrupted in waves.
The most recent wave saw Babylon Health, valued at $4.2 billion in its latest funding round, explode on the scene with an AI-powered platform for virtual clinical operations. Babylon is about to go public via a SPAC deal through a $4.2-billion merger with Alkuri Global Acquisition Corp., led by former Groupon executives.
It’s also been disrupted by Teladoc Health, the $25-billion telemedicine behemoth that has nicely rewarded investors. Investors who jumped in on this in early 2018 could have seen gains of over 1,500% by January this year.
When we miss one wave, we move on to the next because the healthcare industry is set to see wave after wave of disruption, and Cara comes next.
Set to launch by the end of October, Cara is about to go mainstream, and because of the global experts behind it, it stands a good chance of becoming the next app to go from zero to hero—and perhaps to billions.
unfettered access to a data goldmine
A Global Library of Medicine (GLM) that is continually updated and referenced by its AI engine that will eventually scale up to all ~10,000 diseases known to man
Proprietary IP that could one day be worth billions of dollars
Massive growth runways
The next healthcare disruption is about empowering consumers to take better care—and control—of their health, and early-in investors may have a unique opportunity here with a new app that puts another big patch on a broken healthcare system.
Other companies looking to transform healthcare:
American Well Corp (NYSE:AMWL) is a privately-held company that provides video and voice services to health care providers for their patients, as well as other businesses like banks, insurance companies, retailers and government agencies. They are the largest provider of these services in the United States. The company was founded over 30 years ago by Dr. Alan Greenspan with one guiding principle: “to help people live better lives” (American Well).
The American Well team is made up of nearly 1,000 employees who work together to make sure customers receive service 24 hours a day every day of the year through innovative technologies like HD video collaboration rooms or patient kiosks which provide customer self-service capabilities (AMWC).
It’s no doubt that American Well Corp. has its sights set on the future of medication. In fact, a recent survey on the topic conducted by the company suggests that tha decision makers in hospitals, clinicians, and more are looking at telehealth becoming a permanent fixture for care delivery moving forward.
Ido Schoenberg, Chairman and Co-CEO, American Well Corp. explained, “During the pandemic, telehealth proved to be a critical, and in many cases the only connection point between patients and care teams. For many organizations that meant launching and scaling telehealth as quickly as possible. Now, healthcare decision-makers are taking stock of the systems and solutions they implemented, and many are realizing that what proved useful and successful amid emergent situations is simply not robust enough to meet ongoing care delivery goals and need.”
Alphabet Inc (NASDAQ:GOOGL) is a company that is responsible for profitable, long-term growth. They are committed to producing innovative products and services in the Internet space. Their mission is to help make information more accessible and useful for people everywhere while building an organization that can sustain long-term success. Alphabet's core values are based on "a commitment to innovation" which embodies their desire to always do what's right for users first, with data as their guiding principle.
Like Apple, Alphabet Inc., the parent company of Google, is making major waves in the world of health and wellness. From its COVID-19 initiatives to its FitBit product, Google is committed to helping the world live its healthiest life. Perhaps even more importantly, however, it is working on key technology that will help physicians optimize their time and make better choices along the way.
Google’s Care Studio is a brand-new software solution that will help doctors digitalize patient records while keeping this important data private and secure. In a note from the company’s blog, Google explains, “Care Studio streamlines key clinician workflows so that teams can quickly get the information they need to care for patients. It brings together patient records from the multiple EHRs an organization uses – giving clinicians a centralized view of patient data and the ability to search across these records.”
Microsoft Corporation (NASDAQ:MSFT) s a multinational corporation that was founded by Bill Gates and Paul Allen in 1975. With headquarters in Redmond, Washington, the company develops and sells computer software, consumer electronics, personal computers (PCs), video game consoles and online advertising services.
Microsoft Corporation is no stranger to the healthcare industry, either. Just last year, the technology giant expanded its cloud services into healthcare, allowing providers to manage healthcare data at scale, making it easier for clinicians to provide excellent patient experiences, coordinate care, and more, all while keeping data safe and in compliance.
Microsoft Corporation didn’t stop there, either. It has also created new infrastructure to help provide telehealth services and other virtual offerings. Tom McGuinness, Corporate Vice President, Worldwide Health, at Microsoft explained in a company blog post, “We’re introducing new Microsoft Dynamics 365 patient access features to streamline virtual experience for patients by allowing more flexibility in self-scheduling both virtual and in-person appointments through their existing patient portal and integrating virtual health assistants, like the Azure Health Bot service, for triaging, scheduling, and making it seamless to receive follow-up and wellness guidance from their care team.”
Amazon.com, Inc. (NASDAQ:AMZN) the company that started as an online bookstore has grown into one of the largest retailers in the world. The company's retail operations include AmazonFresh (a grocery delivery service), a publishing imprint, and several other subsidiaries such as Twitch Interactive, Inc. and Zappos which offer clothing and shoes respectively. In recent years, it has also diversified from its e-commerce roots to produce consumer electronics like Kindle e-readers, Fire tablets, and TV sets, provide cloud computing services through AWS (Amazon Web Services) and sell digital content through Amazon Prime.
Amazon isn’t all about e-commerce and entertainment, however. It’s also dipping its toes into the healthcare realm with Amazon Care. Initially deployed to help provide Amazon employees and their families with access to immediate high quality medical care through the use of chat and video conference capabilities, the project is now heading to the public. Well, to other businesses, at least.
Additionally, Amazon.com, Inc is also on the cutting edge of artifical intelligence and machine learning in the healthcare realm. Using Amazon’s cloud infrastructure, AWS, companies will be able to make sense of health data, increase the pace of innovation and build new solutions on a trusted platform that will help keep vulnerable data safe and individuals’ privacy as a top priority.
Neuronetics, Inc. (NYSE:STIM) is an industry leader in the development of neuromodulation therapies for neurological disorders and pain management. The company's products are based on a proprietary delivery platform that uses low-intensity electrical currents to stimulate nerve cells in the brain using electrodes on the surface of the head or via implanted leads directly into targeted areas of the nervous system. Neuronetics has developed both investigational devices and FDA-approved therapeutic devices for use in clinical trials, including deep brain stimulation (DBS) therapy for Parkinson’s disease, essential tremor, dystonia and other movement disorders; peripheral nerve field stimulation (PNFS) therapy for chronic neuropathic pain; vagus nerve stimulator therapy for epilepsy treatment-resistant depression among many others.
Neuronetics Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The company’s first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
Working with its NeuroStar therapy system, the company’s TouchStar protocol is a non-drug, non-invasive transcranial magnetic stimulation (TMS) treatment for Major Depressive Disorder (MDD). Greg Harper, Vice President of Product Development and Operations at Neuronetics, explained, The TouchStar protocol is particularly impactful when paired with our patented Contact Sensing precision technology that provides clinicians with the confidence of knowing they are giving patients the right dose at the exact location."
Telehealthcare has been a hot topic in the healthcare industry for years. Companies like Teladoc Health Inc (NYSE:TDOC), which offer remote consultations with doctors and nurses, have created an opportunity for patients to receive care from afar. This is especially important for those who need access to medical care but are unable to travel due to work or other obligations such as children or elderly parents. As more people use these services they will become more commonplace and continue to change the landscape of how health care is delivered around the world.
On October 6th, Teledoc Health Inc announced that its primary care service, Primary360, will be available to commercial health plans, employers, and other organizations that sponsor health care for individuals and families in the United States. This is huge because it will open the door to a massive amount of people who may have otherwise fallen between the cracks.
Donna Boyer, chief product officer at Teladoc Health, explained, Primary360 has the unique power to drive the unified health care experience that consumers are demanding by removing longstanding barriers like access, cost and convenience,” adding “Primary360 gives people greater control over their healthcare experience without losing the personal connection they seek – all from a brand that they trust.”
3D Signatures Inc (CVE:DXD) is a high-tech Canadian firm that has found itself in the center of two explosive sectors. It’s armed with an innovative new software platform which uses 3D analysis to target various diseases and help clinicians identify a diagnosis and optimize treatment plans. 3D Signatures’ software is saving doctors time which could be the difference of life and death for some patients. 3D Signatures sets itself apart from its competition through creating individualized treatment plans for patients. Using its mapping platform, the software can determine how a disease will progress and whether or not the patient will respond to treatment
3D Signatures’ broad scope and futuristic technology brings a promising opportunity to potential investors. It truly is at the forefront of a new era in medicine, and investors should not overlook this company’s massive potential.
CRH Medical Corporation (TSX:CRH) specializes in products and services designed for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. With a long history within the space, CRH has positioned itself as a leader in the field, trusted by medical professionals all over the world.
CRH also made a majpr acquisition at the beginning of the year, buying out Anesthesia Care Associates, LLC, an Indiana-based gastroenterology anesthesia practice. The estimated $2.6 million deal will increase CRH’s footprint in the space, and has been well received by investors.
AEterna Zentaris Inc. (TSX:AEZS) is a major biopharmaceutical up and comer. The company has seen steady growth, and an array of new developments over the recent years. With a focus on oncology, endocrinology, and women's health solutions, AEterna has created a variety of new products, including Macrilen, the first and only FDA-approved oral test for the diagnosis of Adult Growth Hormone Deficiency.
Recently, AEterna received European approval to market Macrillen which has pushed its value even higher. Dr. Christian Strasburger, the Head of Clinical Endocrinology at Charité Unversitaetsmedizin Berlin and the principal investigator for macimorelin explained, “Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the current methods of testing for insulin-induced hypoglycemia, and is well-tolerated by patients and reliable in diagnosing the condition.”
Aptose Biosciences Inc. (TSX:APS) is a biotech company specializing in personalized therapies to address Canada’s unmet oncology needs. The company uses genetic and epigenetic profiles to gain insights into certain cancers and patient populations in order to develop new treatments within the space.
Aptose has an exclusive partnership with Ohm Oncology to develop, manufacture and commercialize APL-581 in order to treat hematologic malignancies and related molecules.
Toronto-based Field Trip Health (CSE:FTRP) is taking a three-pronged approach in their work in the transformative psychedelic medicine sector. Not only are they involved in drug development, but they’re also involved in manufacturing and run a number of treatment clinics.
Field Trip has hit the ground running. With clinics currently operating in Toronto, Los Angeles, and New York, they have plans to ramp up to 75 clinics – providing psychotherapy along with psychedelic treatments. As one of the frontrunners in this exciting new industry, investors are keeping a close eye on Field Trip.
By. Charles Kennedy
** IMPORTANT NOTICE AND DISCLAIMER — PLEASE READ CAREFULLY! **
PAID ADVERTISEMENT. This article is a paid advertisement. Advanced Media Solutions Ltd. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Treatment.com International, Inc. Inc. (“Treatment.com” or “Company”) to conduct investor awareness advertising and marketing. Treatment.com paid the Publisher to produce and disseminate six articles profiling the Company at a rate of seventy-five thousand US dollars per article. This compensation should be viewed as a major conflict with our ability to be unbiased.
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Treatment.com) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the company’s products, the anticipated growth of the market for AI-assisted products generally, the anticipated growth of the market for app-based products generally, the anticipated launch date for the company’s products, the anticipated growth of the market for health care app-based products generally, the anticipated launch date for the company’s products, and the anticipated growth and expansion of the medical library to which the company’s products have access. Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the AI technology used in the company’s products, the company’s ability to effectively market the company’s products to customers within its three anticipated revenue streams, supply chain constraints, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY. oilprice.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.